+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B



Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B



Journal of Hepatology 38(Suppl. 2): 169




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035233922

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(03)80850-4


Related references

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Suppl. 1): 245, 2002

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B. Scandinavian Journal of Gastroenterology 44(8): 1021-1022, 2010

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 35(3): 406-411, 2001

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences 92(7): 1386-1395, 2003

Durability of HBeAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy. Journal of Hepatology 34(Suppl. 1): 155, 2001

Higher efficacy of sequential therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg positive, chronic hepatitis B patients. Gastroenterology 123(1 Suppl.): 69, 2002

Lamivudine monotherapy and interferon plus lamivudine combination therapy in anti-HBe positive patients with chronic hepatitis B who have failed previously interferon treatment. Journal of Hepatology 34(Suppl. 1): 167, 2001

Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian Journal of Gastroenterology 25(3): 136-139, 2006

Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Digestive Diseases and Sciences 52(3): 727-731, 2007

Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis. Zhonghua Gan Zang Bing Za Zhi 19(1): 29-33, 2011